Latest stories on ANIP
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
GlobeNewswire50 · neutralearnings
ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
Business Insider50 · neutralearnings
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
Business Insider58 · neutralproduct/pr
ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
Seeking Alpha67 · bullishanalyst
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
Business Insider73 · bullishproduct/pr
ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
ANI Pharmaceuticals initiated with an Outperform at Leerink
The Fly61 · neutralanalyst
ANI Pharmaceuticals to Present at September Investor Conferences
Business Insider56 · neutralgeneral
ANI Pharmaceuticals to Present at September Investor Conferences
GlobeNewswire56 · neutralgeneral
ANI Pharmaceuticals reshapes board to advance rare disease strategy
TipRanks56 · neutralgeneral
ANI PHARMACEUTICALS INC (ANIP) files 8-K
SEC 8-K50 · neutralgeneral
ANI Pharmaceuticals Earnings Call Signals Growth Momentum
TipRanks63 · neutralearnings
ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript
The Motley Fool67 · bullishearnings
ANI Pharmaceuticals price target lowered to $119 from $124 at Guggenheim
The Fly42 · neutralanalyst
ANI Pharmaceuticals price target lowered to $90 from $91 at Canaccord
The Fly48 · neutralanalyst
ANI Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Yahoo Top50 · neutralearnings
ANI projects $1.08B-$1.14B 2026 revenue as it revises Cortrophin to $520M-$540M amid gout sales force expansion
Seeking Alpha63 · neutralearnings
ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
ANI Pharmaceuticals Shares Slide Despite Earnings Beat After Cortrophin Outlook Cut
InvestorsHub38 · neutralearnings
ANI Pharmaceuticals Posts Record Q2 2026 Results
TipRanks73 · bullishearnings
ANI PHARMACEUTICALS INC (ANIP) files 8-K
SEC 8-K50 · neutralgeneral
Ani Pharmaceuticals Backs Fy26 Adjusted Eps View 9 19 9 69 Consensus 9 42
The Fly58 · neutralearnings
ANI Pharmaceuticals backs FY26 revenue view $1.08B-$1.14B, consensus $1.12B
The Fly56 · neutralearnings